These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 8691580)

  • 1. Intracellular pharmacodynamics in leukemia therapy.
    Gandhi V; Estey EH; Keating MJ; Plunkett W
    Rinsho Ketsueki; 1996 May; 37(5):369-79. PubMed ID: 8691580
    [No Abstract]   [Full Text] [Related]  

  • 2. Lung toxicity following fludarabine, cytosine arabinoside and mitoxantrone (flan) treatment for acute leukemia.
    Salvucci M; Zanchini R; Molinari A; Zuffa E; Poletti V; Poletti G; Zaccaria A
    Haematologica; 2000 Jul; 85(7):769-70. PubMed ID: 10897135
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacologically directed design of leukemia therapy.
    Plunkett W; Heinemann V; Estey E; Keating M
    Haematol Blood Transfus; 1990; 33():610-3. PubMed ID: 2182451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
    Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W
    Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
    Gandhi V; Estey E; Du M; Keating MJ; Plunkett W
    Clin Cancer Res; 1997 Sep; 3(9):1539-45. PubMed ID: 9815841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of arabinosylcytosine metabolism during leukemia therapy.
    Gandhi V; Estey E; Plunkett W
    Adv Exp Med Biol; 1994; 370():119-24. PubMed ID: 7544948
    [No Abstract]   [Full Text] [Related]  

  • 7. Changing the way we think about chronic lymphocytic leukemia.
    Lin TS; Grever MR; Byrd JC
    J Clin Oncol; 2005 Jun; 23(18):4009-12. PubMed ID: 15767640
    [No Abstract]   [Full Text] [Related]  

  • 8. [Mitoxantrone-aracytine with or without quinine in the treatment of refractory or relapsed acute leukemia].
    Solary E; Witz F; Moreau P; Quiquandon I; Genne P; Flesch M; Saddoun A; Maloisel F; Pignon B; Abgrall JF
    Nouv Rev Fr Hematol (1978); 1994 Jul; 36 Suppl 2():S141-3. PubMed ID: 7971263
    [No Abstract]   [Full Text] [Related]  

  • 9. Mitoxantrone.
    Med Lett Drugs Ther; 1988 Jul; 30(769):67-8. PubMed ID: 3380059
    [No Abstract]   [Full Text] [Related]  

  • 10. Fludarabine, cytarabine and topotecan (FLAT) as induction therapy for acute myeloid leukemia in the elderly: a preliminary report.
    Leoni F; Ciolli S; Nozzoli C; Santini V; Fanci R; Rossi Ferrini P
    Haematologica; 2001 Jan; 86(1):104. PubMed ID: 11146581
    [No Abstract]   [Full Text] [Related]  

  • 11. Mitoxantrone and cytosine arabinoside (ARA-C) in adult acute leukemia: an interim report.
    Kansu E; Koc Y; Kars A; Alakavuklar M; Tekuzman G; Firat D
    J Chemother; 1989 Jul; 1(4 Suppl):1268-70. PubMed ID: 16312861
    [No Abstract]   [Full Text] [Related]  

  • 12. The treatment of patients with acute nonlymphocytic leukemia in remission.
    Preisler HD; Raza A; Rustum Y; Browman G
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):91-7. PubMed ID: 4012344
    [No Abstract]   [Full Text] [Related]  

  • 13. Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem cell transplantation in acute myeloid leukemia patients.
    Visani G; Lemoli RM; Isidori A; Piccaluga PP; Martinelli G; Malagola M; Gugliotta L; Bonini A; Bonifazi F; Motta MR; Rizzi S; Castellani S; Tura S
    Bone Marrow Transplant; 2001 Apr; 27(8):829-35. PubMed ID: 11477440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frontline therapy for chronic lymphocytic leukemia: the dilemma continues.
    Nabhan C
    Clin Cancer Res; 2008 Jul; 14(13):4353. PubMed ID: 18594019
    [No Abstract]   [Full Text] [Related]  

  • 15. Gene expression profiles of two accelerations in a CML patient.
    Fiser K; Klamová H; Moravcová J
    Leuk Res; 2006 Jun; 30(6):751-3. PubMed ID: 16289682
    [No Abstract]   [Full Text] [Related]  

  • 16. Fludarabine, cytarabine, and mitoxantrone (FLAM) for the treatment of relapsed and refractory adult acute lymphoblastic leukemia. A phase study by the Polish Adult Leukemia Group (PALG).
    Giebel S; Krawczyk-Kulis M; Adamczyk-Cioch M; Jakubas B; Palynyczko G; Lewandowski K; Dmoszynska A; Skotnicki A; Nowak K; Holowiecki J;
    Ann Hematol; 2006 Oct; 85(10):717-22. PubMed ID: 16832677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A combination therapy with fludarabine, mitoxantrone and rituximab induces complete immunophenotypical remission in B-cell prolymphocytic leukaemia.
    Tempescul A; Feuerbach J; Ianotto JC; Dalbies F; Marion V; Le Bris MJ; De Braekeleer M; Berthou C
    Ann Hematol; 2009 Jan; 88(1):85-8. PubMed ID: 18654781
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical challenges in chronic lymphocytic leukemia.
    O'Brien S
    Semin Hematol; 1998 Jul; 35(3 Suppl 3):22-6. PubMed ID: 9685176
    [No Abstract]   [Full Text] [Related]  

  • 19. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule.
    Seymour JF; Huang P; Plunkett W; Gandhi V
    Clin Cancer Res; 1996 Apr; 2(4):653-8. PubMed ID: 9816215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Remission in T-cell prolymphocytic leukemia during the FMC treatment course].
    Valiev TT; Vinogradova IuE; Chernova NG; Mar'in DS; Volkova IaK; Petrova VI; Bulanov AIu; Kalinin NN; Semenova EA; Gretsov EM; Kravchenko SK; Kremenetskaia AM; Vorob'ev AI
    Ter Arkh; 2006; 78(7):87-90. PubMed ID: 16944758
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.